Raltegravir intensification shows differing effects on CD8 and CD4 T cells in HIV-infected HAART-suppressed individuals with poor CD4 T-cell recovery

Background:Immunodiscordant HIV-infected patients show viral suppression during antiretroviral therapy but fail to recover CD4 T cells. Immunodiscordance is characterized by partial CD4 T-cell immunodeficiency and increased inflammation, activation and immunosenescence in both CD4 and CD8 T cells. Methods:A randomized, controlled, 48-week intensification study to assess the effect of raltegravir on immunological parameters in immunodiscordant patients (CD4 cell counts <350 cells/&mgr;l; viral load <50 copies/ml for >2 years). Patients were randomized (2 : 1) to intensify therapy with raltegravir (intensified arm, n = 30) or continue with the same therapy (control arm, n = 14). Results:Both groups showed similar immunological baseline characteristics. CD4 T-cell counts increased faster in the intensified arm (P = 0.01, week 12). However, no differences between groups were observed at week 48. Additionally, no changes in thymic output (CD45RA+CD31+ cells), activation (HLA-DR+CD95+ cells) or ex-vivo cell death were observed in CD4 T cells at any time point intergroups or intragroups. Conversely, intensified arm showed significant decreases in the expression of the CD8 T-cell activation marker CD38 at weeks 24–48, which were more evident in memory cells. Despite this, the levels of HLA-DR expression in CD8 T cells and plasma soluble CD14 remained stable in both arms overtime. Conclusion:Long-term (48-week) raltegravir intensification failed to counterbalance CD4 T-cell deficiency and its associated features: hyperactivation and death of CD4 T cells. However, raltegravir induced a specific reduction of CD38 expression in CD8 T cells, suggesting a beneficial effect on CD8 T-cell hyperactivation, which has been linked with HIV-associated comorbidities.

[1]  J. Benito,et al.  Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir , 2012, AIDS.

[2]  B. Clotet,et al.  Treatment Intensification with Raltegravir in Subjects with Sustained HIV-1 Viraemia Suppression: A Randomized 48-Week Study , 2012, Antiviral therapy.

[3]  S. Lewin,et al.  Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial. , 2011, The Journal of infectious diseases.

[4]  M. Lederman,et al.  Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells. , 2011, The Journal of infectious diseases.

[5]  M. Clerici,et al.  Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. , 2011, Blood.

[6]  D. Boulware,et al.  Higher levels of CRP, D-dimer, IL-6, and hyaluronic acid before initiation of antiretroviral therapy (ART) are associated with increased risk of AIDS or death. , 2011, The Journal of infectious diseases.

[7]  P. D. de Bakker,et al.  Comparative transcriptomics of extreme phenotypes of human HIV-1 infection and SIV infection in sooty mangabey and rhesus macaque. , 2011, The Journal of clinical investigation.

[8]  J. Reynes,et al.  Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. , 2011, Blood.

[9]  Jeffrey N. Martin,et al.  Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. , 2011, The Journal of infectious diseases.

[10]  G. Carcelain,et al.  HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. , 2011, Blood.

[11]  A. d’Arminio Monforte,et al.  Evidence for Polymicrobic Flora Translocating in Peripheral Blood of HIV-Infected Patients with Poor Immune Response to Antiretroviral Therapy , 2011, PloS one.

[12]  Jeffrey N. Martin,et al.  A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. , 2011, The Journal of infectious diseases.

[13]  M. Si-Tahar,et al.  Innate Sensing of HIV-Infected Cells , 2011, PLoS pathogens.

[14]  A. Sharrett,et al.  T Cell Activation and Senescence Predict Subclinical Carotid Artery Disease in HIV-Infected Women , 2011, The Journal of infectious diseases.

[15]  C. B. Hare,et al.  Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy , 2010, AIDS.

[16]  P. Mas,et al.  Structure and inhibition of herpesvirus DNA packaging terminase nuclease domain , 2010, Proceedings of the National Academy of Sciences.

[17]  M. Lederman,et al.  The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial , 2010, PLoS medicine.

[18]  F. Villarroya,et al.  Nadir CD4 T cell count as predictor and high CD4 T cell intrinsic apoptosis as final mechanism of poor CD4 T cell recovery in virologically suppressed HIV-infected patients: clinical implications. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  B. Clotet,et al.  CD4 T-cell hyperactivation and susceptibility to cell death determine poor CD4 T-cell recovery during suppressive HAART , 2010, AIDS.

[20]  B. Clotet,et al.  Changes in T-cell subsets in HIV–HCV-coinfected patients during pegylated interferon-α2a plus ribavirin treatment , 2010, Antiviral therapy.

[21]  Sarah Palmer,et al.  HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects , 2010, Nature Medicine.

[22]  Giulia Marchetti,et al.  The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  V. Appay,et al.  Phenotype and function of human T lymphocyte subsets: Consensus and issues , 2008, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[24]  J. Brenchley,et al.  Microbial translocation is a cause of systemic immune activation in chronic HIV infection , 2006, Retrovirology.

[25]  M. Lederman,et al.  Interferon-α differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection , 2006 .

[26]  M. Lederman,et al.  Interferon-alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection. , 2006, AIDS.

[27]  A. Flahault,et al.  Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. , 2005, The Journal of infectious diseases.

[28]  J. Barretina,et al.  R5 HIV gp120‐mediated cellular contacts induce the death of single CCR5‐expressing CD4 T cells by a gp41‐dependent mechanism , 2004, Journal of leukocyte biology.

[29]  J. Barretina,et al.  Immunological and virological study of enfuvirtide-treated HIV-positive patients , 2004, AIDS.

[30]  M. Kazatchkine,et al.  Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease , 1998, AIDS.

[31]  C. Sabin,et al.  Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients. , 1996, AIDS.

[32]  J. Margolick,et al.  CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+ CD38- CD8+ cells is associated with subsequent stable CD4+ cell levels. The Multicenter AIDS Cohort Study Group. , 1994, The Journal of infectious diseases.